NCT06545136 - Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions

Gaucher Disease, Type 1

Interventions

GENETIC

FLT201

FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.

Trial Locations (4)

22030-6066

NOT_YET_RECRUITING

Lysosomal Rare Disorders Research and Treatment Center, Fairfax

Unknown

NOT_YET_RECRUITING

Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre

RECRUITING

Hospital Quironsalud Zaragoza, Zaragoza

NOT_YET_RECRUITING

Salford Royal Hospital, Salford